Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
11/2010
11/23/2010US7838505 using hybrid Hepatocyte Growth Factor (HGF) construct for prevention and treatment of ischemic and liver disorders
11/23/2010US7838497 Pro-angiogenic peptides
11/23/2010US7838496 solid phase synthesis; solution phase synthesis; hairpin motifs; chemokine receptor 4 antagonists
11/23/2010US7838495 Compositions and methods of use of EPB1, and ErbB3 binding protein
11/23/2010US7838494 inducing differentiation of bone marrow cells into alveolar cells via administering recombinant hepatocyte growth factor to mammals having lung diseases, pulmonary emphysema
11/23/2010US7838493 Acetylcholinesterase (ACHE)-derived peptide as an inducer of granulocytopoiesis, uses and methods thereof
11/23/2010US7838492 Recombinant canine thyroid stimulating hormone and methods of production and use thereof
11/23/2010US7838491 controlling hydroxyapatite crystal growth; stabilized cylindrical micelles; bone disorders
11/23/2010US7838490 via blocking proteins and signal transduction pathways, with peptide which inhibits p21-activated kinase (PAK)-PIX-GIT interaction or complex formation; mitogen-activated protein kinase inhibitors; tissue damage, ischemia, inflammation, stroke, wound healing, acute respiratory distress syndrome
11/23/2010US7838489 tumor necrosis factor (TNF) receptors, immunoglobuin fusion proteins; anti-tumor necrosis factor antibodies; Crohn's disease, and acute and chronic immune diseases associated with transplantation
11/23/2010US7838294 Inhibitors of the JNK signal transduction pathway and methods of use
11/23/2010US7838277 Viral vector comprising adenovirus capsid gene sequences for use as tool for delivery and expression of heterologous gene sequences in cells
11/23/2010US7838275 Anti-HIV and anti-tumor peptides and fragments of lysozyme
11/23/2010US7838268 selectively modulating NF (Nuclear Factor)- kappa B dependent gene transcription in a cell comprised of modulating I kappa B kinase (IKK) alpha protein activity in the cell
11/23/2010US7838266 A purified pro-cytolytic peptide; used to treat localized and metastatic prostate cancer; administered intratumorally and/or intraprostatically
11/23/2010US7838253 Using cold and menthol-sensitive receptor (CMR1) polypeptide as diagnostic tool in identifying modulators for treatment of pain and cold sensitivity
11/23/2010US7838248 anti-IL-18 Receptor accessory protein antibody; used in the study of cell signaling in response to IL-18 stimulation, and inducible protein expression systems based on the involvement of ACPL polypeptides in cell signaling
11/23/2010US7838247 determination of the Alzheimer Related Membrane Protein (ARMP) gene on chromosome 14 and a related gene, E5-1, on chromosome 1; diagnosing Alzheimer's disease
11/23/2010US7838216 Human gene related to but distinct from EGF receptor gene
11/23/2010US7838122 biodegradable hydrogel FGF-beta mimetic; PEG-dihydrazide crosslinking agent for a desamino-tyrosyl-tyrosine dipeptide or polypeptides thereof; implantable resorbable medical device; wound healing; the water soluble polymer can also be polysaccharide, polyvinyl alcohol or poly(N-methyl pyrrolidone)
11/23/2010US7838024 Multicompartment drug delivery system for use in treatment of menopausal symptoms and benign ovarian secretory disorder; contraceptive
11/23/2010US7838020 Cosmetic or dermatological composition comprising an association between a compound of the N-acylaminoamide family and at least one matrix metalloproteinase inhibitor
11/23/2010US7838015 Adjuvanted meningococcus compositions
11/23/2010US7838009 treating a subject with a kidney obstructed by a naturally formed kidney stone or a subject with a pancreas obstructed by naturally formed pancreatic duct stone by direct injection of an effective amount of a solution or suspension of botulinum toxin into the obstructed kidney or obstructed pancreas
11/23/2010US7838008 Locally administering a botulinum neurotoxin to a cancer or to the vicinity of the afflicted atypical tissue
11/23/2010US7838007 Methods for treating mammary gland disorders
11/23/2010US7838001 Synthetic peptides useful in biological essays for detecting infections caused by group O HIV-1 viruses
11/23/2010US7838000 delivery of a polypeptide comprising at least a portion of the G domain of the laminin-5 alpha 3 chain that has been shown to bind alpha 6 beta 1 integrin receptors and alpha 6 beta 4 integrin receptors; breast cancer
11/23/2010US7837999 fusion polypeptide comprises an insulin-like growth factor 1 (IGF1) variant polypeptide component and a fusion component that is an Fc domain of human IgG; used where muscle atrophy or sarcopenia results from cachexia, immobilization, aging, chronic disease, or cancer
11/23/2010US7837998 Anti-cancer activity of an anti-thymidine kinase monoclonal antibody
11/23/2010US7837997 Compositions and methods for prevention and treatment of uncontrolled formation of intravascular fibrin clots
11/23/2010US7837995 Anticancer agents; low dosage; side effect reduction
11/23/2010US7837993 Methods and compositions for regeneration of aged skeletal muscle tissues
11/23/2010US7837992 C-1 inhibitor prevents non-specific plasminogen activation by a prourokinase mutant without impeding fibrin-specific fibrinolysis
11/23/2010US7837991 detecting an inhibitor of p53 protein degradation comprising providing a cell extract containing one or more p53 protein proteases; capable of modulating calpaine activity
11/23/2010US7837878 very large pore hemofiltration to treat inflammatory mediator related disease (IMRD), hepatic failure, exogenous intoxication and other conditions associated with toxins in a patient's blood
11/23/2010CA2478094C Methods of inducing terminal differentiation
11/23/2010CA2397200C Use of relaxin to treat diseases related to vasoconstriction
11/23/2010CA2385150C Vascular coating composition
11/23/2010CA2385049C Cyclised conotoxin peptides
11/23/2010CA2382133C Phospholipid-based powders for drug delivery
11/23/2010CA2373302C Conditioned cell culture medium compositions and methods of use
11/23/2010CA2354148C Aerosol formulations for buccal and pulmonary application
11/23/2010CA2343655C Interleukin 17-like receptor protein
11/23/2010CA2342200C Use of certain drugs for treating nerve root injury
11/23/2010CA2315271C Platelet derived growth factor (pdgf) nucleic acid ligand complexes
11/23/2010CA2295189C Type-1 ribosome-inactivating protein
11/23/2010CA2258125C T-cell epitope peptides
11/23/2010CA2232738C Strategy for suppressing the expression of an endogenous gene
11/23/2010CA2223989C Prodrugs of pharmaceuticals with improved bioavailability
11/23/2010CA2209301C Redirection of cellular immunity by protein-tyrosine kinase chimeras
11/23/2010CA2194501C Method of regulating immune function
11/23/2010CA2169292C Improved compositions and methods for the delivery of biologically active molecules using genetically altered cells contained in biocompatible immunoisolatory capsules
11/23/2010CA2132421C Broadly reactive opsonic antibodies that react with common staphylococcal antigens
11/18/2010WO2010132867A1 Vaccine immunotherapy
11/18/2010WO2010132827A1 Low-molecular dextran for powder inhalations
11/18/2010WO2010132770A1 Treatment of klebsiella pneumoniae infections with antibacterial aminoglycoside compounds
11/18/2010WO2010132725A2 Cyclin dependent kinase inhibitors and methods of use
11/18/2010WO2010132690A2 Compositions and methods for promoting tissue repair and wound healing
11/18/2010WO2010132687A1 Compositions and methods for modulating cell differentiation
11/18/2010WO2010132683A1 Methods and compositions for treating lupus
11/18/2010WO2010132622A2 Anticd20-cpg conjugates and methods of treating b cell malignancies
11/18/2010WO2010132609A2 Methods and compositions for treating neurodegenerative disorders and alzheimer's disease and improving normal memory
11/18/2010WO2010132580A2 Methods of inhibiting the ghrelin/growth hormone secretatogue receptor pathway and uses thereof
11/18/2010WO2010132561A2 New human rotavirus strains and vaccines
11/18/2010WO2010132537A1 Compounds for, and methods of, treating cancer and inhibiting invasion and metastases
11/18/2010WO2010132407A1 Composition for headache treatment
11/18/2010WO2010132370A2 Soluble tlt-1 for the treatment and diagnosis of sepsis
11/18/2010WO2010132163A1 Macrocyclic compounds as hepatitis c virus inhibitors
11/18/2010WO2010131952A1 Method for controlling the digestive coagulation of proteins
11/18/2010WO2010131909A2 Pharmaceutical preparation to be administered into respiratory organs for treating or preventing inflammatory respiratory diseases, and method for treating or preventing such diseases
11/18/2010WO2010131703A1 NOVEL PPARγ PROMOTER SEQUENCE AND USE APPLICATION THEREOF
11/18/2010WO2010131452A1 Ttk peptides and vaccines including the same
11/18/2010WO2010131382A1 Muscle repair promoter
11/18/2010WO2010131283A1 Peptide able to disrupt the protein complex between the his273 mutaded p53 protein and the oncosuppressive p73 protein in tumour cells and therapeutic uses thereof
11/18/2010WO2010131237A1 A process for producing a biologically active globular protein complex
11/18/2010WO2010131117A1 Use of inclusion bodies as therapeutic agents
11/18/2010WO2010131116A2 Use of lipid conjugates in the treatment of diseases associated with vasculature
11/18/2010WO2010131015A1 Method of labelling interferons with peg
11/18/2010WO2010130956A1 Peptides increasing the secretion and/or expression of at least one gastrointestinal mucin and/or inducing an increase in the population of mucus cells or paneth cells
11/18/2010WO2010130756A1 Immortalized avian cell lines and use thereof
11/18/2010WO2010130753A1 Method for orthopoxvirus production and purification
11/18/2010WO2010130646A1 Lactoferrin and brain health and protection in adults
11/18/2010WO2010130644A1 Combination of (a) a phosphoinositide 3-kinase inhibitor and (b) an antidiabetic compound for use in the treatment of proliferative diseases
11/18/2010WO2010130643A1 Lactoferrin and brain health and development in infants
11/18/2010WO2010130641A1 Lactoferrin and neuronal health and development in the infant gut
11/18/2010WO2010130622A1 Enzyme composition for the treatment of prancreatic insufficiency
11/18/2010WO2010130418A2 Treatment of eye diseases using encapsulated cells encoding and secreting a neuroprotective factor and/or an anti-angiogenic factor
11/18/2010WO2010130073A1 Itgb4bp and derivative thereof used in treatment and/or prevention of hyperplastic scar and fibrosis
11/18/2010WO2010130053A1 COMPOSITIONS AND METHODS FOR TREATING HEMATOLOGIC CANCERS TARGETING THE SIRPα - CD47 INTERACTION
11/18/2010WO2010130007A1 Antimicrobial compounds
11/18/2010WO2010113176A3 Novel copolymers for controlled release delivery system
11/18/2010WO2010111617A3 Parathyroid hormone peptides and parathyroid hormone-related protein peptides and methods of use
11/18/2010WO2010110931A3 Glycoconjugate vaccines
11/18/2010WO2010106441A3 Peptidomimetics for modulating interleukin-1 receptor
11/18/2010WO2010096681A3 Modifications of cupredoxin derived peptides and methods of use thereof
11/18/2010WO2010096572A3 Synthetic diblock copolypeptide hydrogels for use in the central nervous system
11/18/2010WO2010092218A3 Use of cardiotrophin- 1 for the treatment of metabolic diseases
11/18/2010WO2010083842A3 Expression of neuropeptides in mammalian cells
11/18/2010WO2010081091A3 Therapeutic compositions for treatment of corneal disorders
1 ... 553 554 555 556 557 558 559 560 561 562 563 564 565 566 567 568 569 570 571 572 573 ... 3163